- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00656968
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection (960025)
Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter pylori is a bacteria that infects the lining of the stomach and is associated with ulcers. Helicobacter pylori may also increase the long-term risk of developing certain forms of gastric cancer. Curing this infection generally requires that patients take 2 or more antibiotic medications and a stomach acid suppressing medication for about two weeks. Current treatments do not always cure the infection and a new treatment is being tested in this study. The drugs involved in the new 4 drug treatment have been widely used for treatment of this infection. It remains unknown what is the best and most cost effective way to give them. This study will compare three different ways of using these drugs.
Subjects must have active Helicobacter pylori infection in order to participate in this study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to compare different methods of giving combination drug therapy for treating Helicobacter pylori infection of the stomach. The entire study will last less than 2 years. Each subject will be participating in the study for approximately 60 days.
A total of 360 subjects will be asked to participate in this study.
Before participating in this study, subject's must have undergone to confirm the presence and to assess the susceptibility of Helicobacter pylori. Qualified subjects will receive 4 drugs which are to be taken as part of the study treatment: an acid suppressing drug (name), amoxicillin, clarithromycin and metronidazole. The doses are 1 grams of amoxicillin, 40 mg of esomeprazole (Nexium), 500 mg of metronidazole and 250 mg of clarithromycin. Each drug will be given twice a day to be taken twice a day with the morning and evening meals. Subjects will receive one of three different combinations. The choice of which will be randomly chosen by the use of a computer program. The regimes are: all 4 drugs daily for 5 days, all 4 drugs daily for 10 days, and two drugs (esomeprazole and amoxicillin) for 5 days then all for drugs for 5 additional days.
Subjects will be asked to return within 4 days after completion of the treatment to evaluate how they did with the drugs. They will be asked bring back all unused medication and the bottles or containers that the medicine was packaged in. Your medication use and tolerance to the study drugs will be assessed. The treatment portion of the study will be complete at this point.
Evaluation of the effect of the treatment will take place 4-6 weeks after the end of therapy. Subjects will come back to the study site and will have a UBT or repeat endoscopy, if clinically indicated to verify that the Helicobacter pylori has been cured. Subjects will be asked not to take antibiotics or any other drugs that may affect the outcome of the breath test used to confirm that the treatment was successful.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 813
- Kaohsiung Veterans General Hospital
-
Kaohsiung, Taiwan, 807
- Chung-Ho Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or non-pregnant female aged 18 to 75 years inclusively.
- Mental and legal ability to give a written informed consent.
- Active H. pylori infection.
Exclusion Criteria:
- Previous surgery of the stomach such as partial gastrectomy.
- Use of antibiotics within the preceding 30 days.
- Regular use of bismuth compounds (>3 times per week) in the 30 days before enrollment.
- Presence of serious medical condition(s) precluding participation or endoscopy with biopsy.
- Use of concomitant medication(s) known to interact with study medication.
- Presence of Zollinger-Ellison Syndrome.
- Pregnancy or lactation.
- Allergy to any of the study medications.
- Contraindication(s) to the use of any of the study drugs.
- Participation in a clinical trial within the last 30 days.
- Unwillingness to abstain from alcoholic beverages.
- Patients taking other medications including warfarin, antipsychotics, or chronic NSAIDs will also be excluded. Aspirin at a dose not more than 325 mg/day will be permitted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 10-day concomitant therapy
esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days
|
esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
Other Names:
|
Experimental: 10-day sequential therapy
esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days
|
esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants in Which H. Pylori Was Eradicated
Time Frame: one month after finishing study drugs
|
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test
|
one month after finishing study drugs
|
Number of Participants Who Had Good Drug Compliance
Time Frame: one month after finishing test therapy
|
Good drug compliance is defined as taking equal to or more than 80% of eradication medicines
|
one month after finishing test therapy
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Ching-Kuan Liu, MD, PhD, Kaohsiung Medical Univestity
- Study Chair: David Y Graham, MD, Baylor College of Medicine
- Study Director: Antone R Opekun, PA-C, Baylor College of Medicine
- Principal Investigator: Deng-Chyang Wu, MD PhD, Kaohsiung Medical University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Infections
- Communicable Diseases
- Helicobacter Infections
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Esomeprazole
Other Study ID Numbers
- KMU-IRB00003151
- VGHKS95-CT3-11 (Other Grant/Funding Number: KaohsiungVGH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Infection
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
Damascus HospitalNot yet recruitingHelicobacter Pylori InfectionSyrian Arab Republic
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingHelicobacter Pylori Infection
-
Assiut UniversityRecruiting
-
Shanghai Zhongshan HospitalRecruiting
-
TenNor Therapeutics Inc.CompletedHelicobacter Pylori InfectionChina
-
TenNor Therapeutics (Suzhou) LimitedCompleted
Clinical Trials on 10-day concomitant therapy
-
Incheon St.Mary's HospitalUnknownHelicobacter Pylori InfectionKorea, Republic of
-
Alexandra Hospital, Athens, GreeceHellenic Society of GastroenterologyCompletedH.Pylori Infection | H.Pylori Gastrointestinal Disease | H. Pylori Associated Phlegmonous GastritisGreece
-
Uppsala University HospitalCompleted
-
Changi General HospitalCompletedBacterial Infection Due to Helicobacter Pylori (H. Pylori)Singapore
-
BionovoUnknown
-
Ferring PharmaceuticalsTerminatedChronic Idiopathic ConstipationSweden, Canada, Hungary, United States, Brazil, South Africa, Czech Republic, Germany, Mexico, Poland, Slovakia, United Kingdom
-
National Cancer Center, KoreaCompletedHelicobacter Pylori Infection | Family History of Stomach CancerKorea, Republic of
-
University of CopenhagenOdense University Hospital; University of Bergen; Chr Hansen; Statens Serum Institut and other collaboratorsCompletedRespiratory Tract Infections | Allergy | Gastrointestinal Infections | Days Absent From DaycareDenmark
-
HaEmek Medical Center, IsraelUnknownDistal UreterolithiasisIsrael
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownHelicobacter Pylori InfectionTaiwan